In addition, a phase-II clinical trial has demonstrated that the pan-AKT inhibitor MK2206 could increase pathologic complete response rates when combined with standard neoadjuvant therapy in ER-/PR- and HER2+ BC 86. The gene discussed is AKT1; the disease is breast cancer.